Abstract
Cancer is a disease driven by a combination of inherited risk alleles coupled with the acquisition of somatic mutations, including amplification and deletion of genomic DNA. Potential relationships between the inherited and somatic aspects of the disease have only rarely been examined on a genome-wide level. Applying a novel integrative analysis of SNP and copy number measurements, we queried the tumor and normal-tissue genomes of 178 glioblastoma patients from the Cancer Genome Atlas project for preferentially amplified alleles, under the hypothesis that oncogenic germline variants will be selectively amplified in the tumor environment. Selected alleles are revealed by allelic imbalance in amplification across samples. This general approach is based on genetic principles and provides a method for identifying important tumor-related alleles. We find that SNP alleles that are most significantly overrepresented in amplicons tend to occur in genes involved with regulation of kinase and transferase activity, and many of these genes are known contributors to gliomagenesis. The analysis also implicates variants in synapse genes. By incorporating gene expression data, we demonstrate synergy between preferential allelic amplification and expression in DOCK4 and EGFR. Our results support the notion that combining germline and tumor genetic data can identify regions relevant to cancer biology.
Introduction
In cancer research, scientists typically distinguish between the germline genome (inherited variants) and the somatic genome (acquired mutations). While germline studies identify inherited risks and somatic studies identify drivers of progression, these two domains are rarely integrated. This research addresses a fundamental question: Does a tumor's evolution depend on which inherited alleles are present? If an individual carries two different versions of a gene, and one is more "oncogenic," the tumor may selectively amplify that specific version to gain a competitive growth advantage.
Methodology: The Amplification Distortion Test (ADT)
The researchers developed the Amplification Distortion Test (ADT), a somatic analog of the classic Transmission Disequilibrium Test (TDT) used in family genetics. The logic is straightforward: in a population where individuals are heterozygous for alleles A and B, a tumor undergoing random DNA amplification should copy allele A roughly 50% of the time. A significant deviation from this 1:1 ratio suggests that one allele provides a selective advantage to the tumor.
The study utilized data from 178 glioblastoma multiforme (GBM) patients within The Cancer Genome Atlas (TCGA), integrating SNP array data with gene expression profiles. This allowed the team to determine if "selected" alleles resulted in higher protein-coding activity.
Key Results and Insights
The ADT identified 139 SNPs showing significant allelic imbalance in amplicons. Functional enrichment analysis revealed that these SNPs are concentrated in pathways regulating kinase and transferase activity (e.g., EGFR, KIT, INSR), which are well-known contributors to gliomagenesis.
Interestingly, selection was also found in synapse-related genes, suggesting that neuronal signaling pathways may play a larger role in brain tumor progression than previously recognized. For genes like EGFR and DOCK4, the preferentially amplified allele was associated with significantly higher mRNA expression levels, indicating that selection may target regulatory elements like enhancers. Furthermore, the study found a statistically significant overlap between alleles that increase glioblastoma risk (identified via GWAS) and those selected for amplification within the tumor.
Conclusion and Future Directions
The study confirms that somatic evolution is a selective process where tumors "pick" inherited variants that support survival. While the ADT is currently limited by the frequency of genomic amplification and the resolution of linkage disequilibrium, it provides a powerful framework for identifying cancer-relevant regions. Future applications of this logic to genomic deletions could reveal selection for inactivating variants in tumor suppressor genes, further bridging the gap between inherited risk and somatic progression.
Summary updated